GPCR functional selectivity has therapeutic impact

Furchgott, 1966, The use of β-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor–agonist complexes, Vol.3, 21 Ariens, 1954, Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory, Arch. Int. Pharmacodyn. Ther., 99, 32 Stephenson, 1997, A modification of receptor theory 1956, Br. J. Pharmacol., 11, 379 Urban, 2007, Functional selectivity and classical concepts of quantitative pharmacology, J. Pharmacol. Exp. Ther., 320, 1, 10.1124/jpet.106.104463 Simmons, 2005, Functional selectivity, ligand-directed trafficking, conformation-specific agonism: what's in a name?, Mol. Interv., 5, 154, 10.1124/mi.5.3.4 Mailman, 1998, Functional effects of novel dopamine ligands: dihydrexidine and Parkinson's disease as a first step, 64 Lawler, 1994, Discrete functional selectivity of drugs: OPC-14597, a selective antagonist for post-synaptic dopamine D2 receptors, Soc. Neurosci. Abstr., 20, 525 Neubig, 2007, Missing links: mechanisms of protean agonism, Mol. Pharmacol., 71, 1200, 10.1124/mol.107.034926 Garau, 1978, Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum, Life Sci., 23, 1745, 10.1016/0024-3205(78)90102-9 Kebabian, 1979, Multiple receptors for dopamine, Nature, 277, 93, 10.1038/277093a0 1997 Laduron, 1983, Commentary: dopamine-sensitive adenylate cyclase as a receptor site, 22 Mailman, 1998, Dopamine D1 receptor agonists as antiparkinson drugs, Trends Pharmacol. Sci., 19, 255 Mailman, 2001, Parkinson's disease and D1 dopamine receptors, Curr. Opin. Investig. Drugs, 2, 1582 Bedard, 1989, Effect of D1 receptor stimulation in normal and MPTP monkeys, Neurosci. Lett., 104, 223, 10.1016/0304-3940(89)90358-3 Elliott, 1992, Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset, Neurosci. Lett., 142, 1, 10.1016/0304-3940(92)90606-8 Charifson, 1988, Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands, J. Med. Chem., 31, 1941, 10.1021/jm00118a012 Charifson, 1989, Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands, J. Med. Chem., 32, 2050, 10.1021/jm00129a006 Setler, 1978, The central effects of a novel dopamine agonist, Eur. J. Pharmacol., 50, 419, 10.1016/0014-2999(78)90148-6 Nichols, 1983, The development of novel dopamine agonists, 201 Mottola, 1996, Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping, J. Med. Chem., 39, 285, 10.1021/jm9502100 Lovenberg, 1989, Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist, Eur. J. Pharmacol., 166, 111, 10.1016/0014-2999(89)90690-0 Taylor, 1991, Dihydrexidine, a full dopamine D1 agonist, reduces MPTP-induced parkinsonism in monkeys, Eur. J. Pharmacol., 199, 389, 10.1016/0014-2999(91)90508-N Brewster, 1990, trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist, J. Med. Chem., 33, 1756, 10.1021/jm00168a034 Mottola, 1992, Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist, J. Pharmacol. Exp. Ther., 262, 383 Darney, 1991, Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist, Neuropsychopharmacology, 5, 187 Mottola, 2002, Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase, J. Pharmacol. Exp. Ther., 301, 1166, 10.1124/jpet.301.3.1166 Mottola, 1991, Dihydrexidine, a selective dopamine receptor agonist that may discriminate postsynaptic D2 receptors, Soc. Neurosci. Abstr., 17, 818 Meller, 1987, Relationship between receptor occupancy and response at striatal dopamine autoreceptors, Mol. Pharmacol., 31, 592 Asimov, I. (1971) The Eureka Phenomenon. The Magazine of Fantasy and Science Fiction June Kenakin, 1990, Drugs and receptors. An overview of the current state of knowledge, Drugs, 40, 666, 10.2165/00003495-199040050-00003 O’Hara, 1996, Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors, J. Pharmacol. Exp. Ther., 277, 186 Tang, 1994, Dopamine D2 and D3 receptors inhibit dopamine release, J. Pharmacol. Exp. Ther., 270, 475 Kilts, 2002, Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs, J. Pharmacol. Exp. Ther., 301, 1179, 10.1124/jpet.301.3.1179 Mailman, 1997, Molecular drug design and dopamine receptors, 105 Gay, 2004, Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states, Mol. Pharmacol., 66, 97, 10.1124/mol.66.1.97 Eden, 1991, Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist, Pharmacol. Biochem. Behav., 38, 147, 10.1016/0091-3057(91)90603-Y Smith, 1997, Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist, Eur. J. Pharmacol., 323, 27, 10.1016/S0014-2999(97)00026-5 Delay, 1952, Ann. Med. Psychol. (Paris), 110, 267 Carlsson, 1963, Effect of chlorpromazine and haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain, Acta Pharmacol. Toxicol. (Copenh.), 20, 140, 10.1111/j.1600-0773.1963.tb01730.x Creese, 1976, Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs, Science, 192, 481, 10.1126/science.3854 Tamminga, 2002, Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis, Curr. Drug Targets CNS. Neurol. Disord., 1, 141, 10.2174/1568007024606195 Tamminga, 1978, Schizophrenic symptoms improve with apomorphine, Science, 200, 567, 10.1126/science.347574 Corsini, 1981, The use of dopamine agonists in the treatment of schizophrenia, Neuropharmacology, 20, 1309 Smith, 1977, Effect of apomorphine on schizophrenic symptoms, J. Neural Transm., 40, 171, 10.1007/BF01250567 Tamminga, 1986, Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine 3, Arch. Gen. Psychiatry, 43, 398, 10.1001/archpsyc.1986.01800040108015 Kenakin, 1997 Lahti, 1998, Antipsychotic properties of the partial dopamine agonist (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia, Biol. Psychiatry, 43, 2, 10.1016/S0006-3223(97)00030-9 Tamminga, 1992, Pharmacologic properties of (−)-3PPP (preclamol) in man, J. Neural Transm. Gen. Sect., 88, 165, 10.1007/BF01244730 Tamminga, 2002, Partial dopamine agonists in the treatment of psychosis, J. Neural Transm., 109, 411, 10.1007/s007020200033 Stahl, 2001, Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, ‘Goldilocks’ actions at dopamine receptors, J. Clin. Psychiatry, 62, 841, 10.4088/JCP.v62n1101 Lieberman, 2004, Dopamine partial agonists: a new class of antipsychotic, CNS Drugs, 18, 251, 10.2165/00023210-200418040-00005 Lawler, 1999, Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes, Neuropsychopharmacology, 20, 612, 10.1016/S0893-133X(98)00099-2 Burris, 2002, Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors, J. Pharmacol. Exp. Ther., 302, 381, 10.1124/jpet.102.033175 Shapiro, 2003, Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology, Neuropsychopharmacology, 28, 1400, 10.1038/sj.npp.1300203 Urban, 2007, Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways, Neuropsychopharmacology, 32, 67, 10.1038/sj.npp.1301071 Kikuchi, 1995, 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity, J. Pharmacol. Exp. Ther., 274, 329 Ungerstedt, 1970, Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system, Brain Res., 24, 485, 10.1016/0006-8993(70)90187-3 Friedman, 2006, Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease, Mov. Disord., 21, 2078, 10.1002/mds.21091